7 results about "Cetirizine" patented technology

The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

Described herein is a method of administering injectable cetirizine or levocetirizine to treat acute urticaria, with or without concomitant angioedema, without life-threatening airway swelling by intravenously injecting a human patient within minutes to hours of developing acute urticaria in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition. In the method, the injectable cetirizine or levocetirizine is the only treatment administered in the emergency department or clinic. The method can include determining, by the patient, a patient rated pruritus severity score at a 1 hour assessment, and optionally at a 2 hours assessment, and a physician discharging the human patient after 1.7±0.9 hours in the emergency department or clinic, wherein the human patient has a patient rated pruritus severity score reduction of at least 1 unit and baseline sedation at the time of discharge.

The application belongs to the technical field of colloidal gold immunochromatography, and relates to cetirizine monoclonal antibody, nucleic acid molecules, vectors, detection kits and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises VH-CDR1, VH-CDR2 and VH-CDR3, the light chain variable region comprises VL-CDR1, VL-CDR2 and VL-CDR3, the sequence of VH-CDR1 is shown as SEQ ID NO. 1, the sequence of VH-CDR2 is shown as SEQ ID NO. 2, and the sequence of VH-CDR3 is shown as SEQ ID NO. 3. The monoclonal antibody of the application has high sensitivity to cetirizine, the minimum detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

Methods of using centanafadine in treating ADHD and reducing ADHD symptoms are disclosed.

A method of treating diarrhea in a patient includes administering a dose of 2.0-7.0 mg of cetirizine and 3.0-15.0 mg of famotidine.

The present invention provides a derivative having a tetravalent platinum structure of cetirizine, as well as its preparation method and use. The compound having a tetravalent platinum structure of cetirizine is represented by general formula (I), wherein, #imgabs0#, #imgabs1# is selected from cisplatin or oxaliplatin; L is a hydroxyl group or #imgabs2#. The tetravalent platinum structure of cetirizine described in the present invention inhibits histamine (HA) secretion in tumors through the functional group cetirizine, blocks the HA / HRH1 signaling axis, inhibits the PI3K / AKT / mTOR pathway, and thereby inhibits tumor angiogenesis; induces DNA damage through the platinum nucleus; and the two synergistically exert anti-tumor effects. The compound has significant anti-tumor ability, especially excellent therapeutic effects on metastatic malignant tumors. It is expected to provide a new drug candidate for the clinical treatment of tumors and a new direction for the research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

The invention discloses a method for separating and detecting cetirizine isomers in levocetirizine hydrochloride oral liquid, levocetirizine hydrochloride and dexcetirizine hydrochloride as well as dexcetirizine hydrochloride and pharmaceutical adjuvant peaks can be effectively separated by the separation and detection method, and dexcetirizine hydrochloride can be accurately and efficiently separated and detected by the method. The method can be used for quality control of dexcetirizine hydrochloride drug detection.